Novavax Inc. develops and partners vaccine technologies built around Matrix-M adjuvant technology and protein-based nanoparticles. Company news centers on marketed vaccine products, including Nuvaxovid and R21/Matrix-M, licensing and material-transfer agreements with pharmaceutical companies, and research programs for infectious disease and other vaccine applications.
Recurring updates also cover quarterly financial results, revenue from product sales and partner arrangements, R&D prioritization such as its C. difficile vaccine candidate, operating-efficiency initiatives, investor conference participation, and leadership changes within research and development.
Novavax, Inc. (Nasdaq: NVAX) announced that its COVID-19 vaccine, Nuvaxovid™, received expanded conditional marketing authorization from the UK's Medicines and Healthcare products Regulatory Agency for use in adolescents aged 12 to 17. This marks the first protein-based COVID-19 vaccine available for this age group in the UK. The authorization is based on data from the pediatric expansion of the Phase 3 PREVENT-19 trial, where Nuvaxovid demonstrated 80% clinical efficacy during the Delta variant surge. The next step involves a policy recommendation from the UK Joint Committee on Vaccination and Immunisation.
Novavax, Inc. (Nasdaq: NVAX) announced the FDA has granted expanded emergency use authorization for its COVID-19 Vaccine, Adjuvanted for adolescents aged 12-17. This marks it as the first protein-based COVID-19 vaccine authorized in the U.S. A clinical trial involving 2,247 participants demonstrated an overall efficacy of 78.29% against the Delta variant. Vaccination immunizations for adolescents can start following CDC recommendations. Safety data indicates a well-tolerated profile with mild side effects. The vaccine remains authorized under EUA and is designed to enhance vaccination rates as COVID-19 cases surge.
Novavax, Inc. (Nasdaq: NVAX) announced that New Zealand's Medsafe has granted expanded provisional approval for Nuvaxovid™, a protein-based COVID-19 vaccine, for adolescents aged 12 to 17. This approval allows Nuvaxovid to be used as a primary series and booster for older populations. The decision is based on the Phase 3 PREVENT-19 trial, which showed an 80% clinical efficacy during the Delta variant's prevalence. The vaccine was well-tolerated, with low serious adverse events. Nuvaxovid is already authorized in several countries for this age group, enhancing global vaccination efforts.
Novavax announced that its COVID-19 vaccine, Nuvaxovid™, has received expanded provisional approval from New Zealand's Medsafe. This approval allows Nuvaxovid to be used as both a first and second booster dose for adults aged 18 and older, regardless of the primary vaccine received. As New Zealand faces a surge of COVID-19 cases, Novavax emphasizes its vaccine’s broad immune response to circulating variants. The approval is supported by data from several Phase 2 trials, demonstrating strong immune responses post-booster. Nuvaxovid is also provisionally registered in Australia and approved in Japan.
Novavax has submitted an application to the U.S. FDA for Emergency Use Authorization (EUA) of its protein-based COVID-19 Vaccine, Adjuvanted, as a booster for adults 18 and older. If approved, it would be the first protein-based booster available, complementing immunity from other vaccines. Data from the Phase 3 PREVENT-19 trial indicates that the booster dose generates robust antibody responses. The vaccine aims to enhance immunity against various COVID-19 variants and has previously received EUA for primary vaccination. Robust safety and immune response data back the application.
Novavax, Inc. (Nasdaq: NVAX) and SK bioscience have received approval from the Korean Ministry of Food and Drug Safety for Nuvaxovid, the first protein-based COVID-19 vaccine for adolescents aged 12-17 in South Korea. This approval follows successful data from the Phase 3 PREVENT-19 trial, showing Nuvaxovid achieved 80% clinical efficacy against COVID-19 during the Delta variant surge. The vaccine has also received authorizations in countries like India and the European Union and has demonstrated a favorable safety profile.
Novavax, Inc. (Nasdaq: NVAX) will participate in a fireside chat during the SVB Securities Virtual Vaccine Forum on August 18, 2022, from 11:00 to 11:50 a.m. EDT. The discussion will focus on NVX-CoV2373, Novavax's recombinant nanoparticle protein-based COVID-19 vaccine candidate. Key participants include Filip Dubovsky, M.D., and John J. Trizzino. Novavax's COVID-19 vaccine has received multiple global authorizations and is under review for additional populations. The company is also evaluating a combination vaccine candidate and new Omicron strain-based vaccines.
Novavax (NVAX) has received FDA Emergency Use Authorization for NVX-CoV2373, becoming the first protein-based COVID-19 vaccine authorized for adults in the U.S. The company reported a total revenue of $186 million in Q2 2022, a decline from $298 million the previous year, with adjusted revenue guidance set between $2 billion and $2.3 billion for the year. Despite delivering over 73 million doses globally, Novavax faced a net loss of $510 million. The company continues to progress its variant program, with further clinical data expected.
Novavax announced the initiation of its Phase 2b/3 Hummingbird global clinical trial for the COVID-19 vaccine (NVX-CoV2373) targeting children aged six months to 11 years. The trial will evaluate safety, immunogenicity, and efficacy of two doses, followed by a booster. Enrollment will include 3,600 participants from several countries, with initial results expected in Q1 2023. CEO Stanley C. Erck expressed optimism about expanding vaccine access to all age groups in the ongoing pandemic.
Novavax, Inc. (Nasdaq: NVAX) will report its Q2 2022 financial results and operational highlights on August 8, 2022, after U.S. market close. A conference call is scheduled for 4:30 p.m. EDT, and participants are encouraged to join 10 minutes early. The event will be available for replay starting at 7:30 p.m. EDT on the same day until August 15, 2022. Novavax emphasizes its commitment to developing vaccines for serious infectious diseases, including its COVID-19 vaccine, NVX-CoV2373, now authorized globally.